Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novozymes A/S Lowers FY 2013 Sales Guidance; Raises FY 2013 Earnings Guidance


Friday, 9 Aug 2013 02:00am EDT 

Novozymes A/S announced that its full-year 2013 outlook is adjusted for the unfavorable development in exchange rates since previous guidance and a positive effect from a lower effective tax rate. Sales growth in DKK is expected at a range of between 5% and 7%, EBIT growth at a range of between 4% and 6% and net profit growth of between 7% and 9%. Furthermore, net investments excluding acquisitions are expected to be lower at a range of between DKK 900 million and DKK 1,000 million and free cash flow before acquisitions is adjusted upwards to approximately DKK 1,700 million. Previously, the Company expected to report fiscal year 2013 sales growth in DKK of between 5% and 8%, EBIT growth of between 4% and 7% and net profit growth of between 6% and 9%. It also expected to report fiscal year 2013 net investments excluding acquisitions of approximately DKK 1,100 million and free cash flow before acquisitions of approximately DKK 1,650 million. 

Company Quote

262.9
-9.5 -3.49%
10:59am EST